The oncology-focused company confirmed after Tuesday's market close that the capital raised would be directed toward research and development pipelines, alongside general corporate expenses and working capital requirements. This move signals a significant push to stabilize the company's cash reserves, though shareholders responded by retreating from the stock throughout the Wednesday session.
Summit Therapeutics Shares Hit Yearly Low After $500 Million Offering
Investors pushed Summit Therapeutics to a 52-week low on Wednesday following the company's announcement of a $500 million secondary stock offering. The share price dropped 11% to $12.67 by early afternoon, deepening the biopharmaceutical firm's annual decline to 27% as the market reacted to the impending equity dilution.
Comments (0)
No comments yet. Be the first!